Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin: 2022-2025

Historic EBIT Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -162.54%.

  • InMed Pharmaceuticals' EBIT Margin fell 2535.00% to -162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -167.40%, marking a year-over-year decrease of 2108.00%. This contributed to the annual value of -160.77% for FY2025, which is 1750.00% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' EBIT Margin stood at -162.54%, which was down 16.52% from -139.49% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year EBIT Margin high stood at -20.99% for Q2 2023, and its period low was -1,266.61% during Q2 2022.
  • Over the past 3 years, InMed Pharmaceuticals' median EBIT Margin value was -158.54% (recorded in 2024), while the average stood at -162.31%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 124,562bps in 2023, then plummeted by 13,755bps in 2024.
  • InMed Pharmaceuticals' EBIT Margin (Quarterly) stood at -471.26% in 2022, then soared by 33,862bps to -132.64% in 2023, then slumped by 7,012bps to -202.75% in 2024, then slumped by 2,535bps to -162.54% in 2025.
  • Its EBIT Margin stands at -162.54% for Q3 2025, versus -139.49% for Q2 2025 and -169.43% for Q1 2025.